Jet nebulisers currently dominate the market because they are cost-effective, reliable, and highly versatile in terms of drug compatibility. Their widespread adoption is particularly strong in hospital and emergency settings where clinical familiarity and budget containment are primary considerations.
Mesh nebulisers are gaining rapid traction because they offer superior drug delivery efficiency, near-silent operation, and a compact, portable design. These features make them highly attractive for home healthcare, pediatric, and geriatric populations who require user-friendly devices for managing chronic conditions.
The shift is driven by the rising global burden of chronic respiratory diseases like COPD and asthma, coupled with an aging population that prefers self-management. Additionally, healthcare systems are encouraging home-based treatment to reduce hospital readmission rates and overall healthcare spending.
IoMT is enabling the rise of "connected nebulisers." These smart devices integrate with mobile apps and digital platforms to provide real-time monitoring of medication adherence, dose administration, and disease progression, allowing physicians to make data-driven adjustments to patient treatment plans.
Chronic Obstructive Pulmonary Disease (COPD) holds the largest application share. Due to its progressive nature and the high prevalence of smoking and air pollution, patients with severe COPD rely heavily on nebulisers for consistent medication delivery and management of acute exacerbations.
The Asia-Pacific region is projected to be the fastest-growing market. This growth is fueled by a massive patient pool in countries like China and India, increasing urbanization, rising pollution levels, and improving healthcare infrastructure and affordability.
Sustainability is becoming a key differentiator. Manufacturers like Beurer GmbH have introduced "eco-smart" nebulisers that utilize recyclable materials and energy-efficient components to align with global environmental principles and consumer demand for green medical technology.
Key challenges include stringent regulatory approval processes that can delay commercialization, high R&D costs for advanced devices, and intense competition from alternative drug delivery systems such as dry powder inhalers (DPIs) and metered-dose inhalers (MDIs).
Collaborations, such as the agreement between Aerogen and GSK, are focusing on integrating aerosol drug delivery systems with biologics. These hybrid models aim to enhance treatment outcomes for severe asthma and COPD by providing more targeted and efficient delivery of advanced therapeutic substances.
